<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134612">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02073279</url>
  </required_header>
  <id_info>
    <org_study_id>SA-309JG</org_study_id>
    <nct_id>NCT02073279</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy, safety, pharmacodynamic,
      pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>up to approximately 27 months from first patient in</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate</measure>
    <time_frame>up to approximately 27 months from first patient in</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)</condition>
  <arm_group>
    <arm_group_label>SA237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous SA237</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SA237</intervention_name>
    <arm_group_label>SA237</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. NMO or NMOSD

          -  2. Age 18 to 74 years, inclusive at the time of informed consent.

        Exclusion Criteria:

          -  1. Pregnancy or lactation.

          -  2. Evidence of other demyelinating disease or PML.

          -  3. Known active infection (excluding fungal infections of nail beds or caries
             dentium) within 4 weeks prior to baseline.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatjana Lukic, MD., M.Sc.</last_name>
    <role>Study Director</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical trials information</last_name>
    <email>clinical-trials@chugai-pharm.co.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SA237 Clinical trial</last_name>
    <email>sa237@chugai-pharm.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
